Press release
Amyotrophic Lateral Sclerosis Clinical Trials, Companies, Therapies, Pipeline | Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith
Amyotrophic Lateral Sclerosis Clinical Trials
DelveInsight reports that the Amyotrophic Lateral Sclerosis (ALS) pipeline involves over 75 key companies actively developing more than 80 investigational therapies.
Amyotrophic Lateral Sclerosis Overview:
Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative condition that targets motor neurons. Its development involves both hereditary and sporadic factors, although no single cause has been definitively established. ALS affects both upper and lower motor neurons, often beginning with lower motor neuron degeneration in the proximal limbs, and gradually progresses to paralysis, ultimately resulting in death.
While several mechanisms have been suggested, the precise cause of sporadic ALS remains unclear. Contributing factors may include disruptions in RNA processing that promote prion-like aggregation, mutations in the superoxide dismutase 1 (SOD1) gene causing free radical toxicity, inflammatory processes, and elevated glutamate levels. Familial ALS, a less common form, is frequently associated with genetic mutations-most notably the C9ORF72 repeat expansion and SOD1 mutations. Misfolded SOD1 proteins aggregate toxically, leading to cellular damage and apoptosis, with these mutations typically inherited in an autosomal dominant pattern.
Overall, ALS is a complex disorder with multiple contributing factors rather than a single origin, resulting in a multifactorial and heterogeneous pathogenesis.
Request for a detailed insights report on Amyotrophic Lateral Sclerosis pipeline insights [https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Amyotrophic Lateral Sclerosis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Amyotrophic Lateral Sclerosis Therapeutics Market.
Key Takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report
*
DelveInsight's Amyotrophic Lateral Sclerosis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Amyotrophic Lateral Sclerosis treatment.
*
Key Amyotrophic Lateral Sclerosis companies such as AIonis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics, UCB, and others are evaluating new drugs for Amyotrophic Lateral Sclerosis to improve the treatment landscape.
*
Promising Amyotrophic Lateral Sclerosis pipeline therapies in various stages of development include MN-166, RNS60, VM202, QRL-201, and others.
*
Celosia Therapeutics, a biotech startup from Macquarie University, has secured funding to advance CTX-1000, a potential disease-modifying therapy targeting the TDP-43 protein implicated in ALS pathology. Preclinical studies have shown promise, and human trials are anticipated to commence by late 2025.
*
In April 2023, the FDA approved Qalsody for patients with ALS associated with mutations in the superoxide dismutase 1 (SOD1) gene. Qalsody is an antisense oligonucleotide designed to reduce the synthesis of the SOD1 protein, addressing a specific genetic subset of ALS. The approval was based on observed reductions in plasma neurofilament light (NfL), a biomarker indicative of neuronal injury and degeneration.
Amyotrophic Lateral Sclerosis Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Amyotrophic Lateral Sclerosis Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Amyotrophic Lateral Sclerosis treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Amyotrophic Lateral Sclerosis market.
Download our free sample page report on Amyotrophic Lateral Sclerosis pipeline insights [https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Amyotrophic Lateral Sclerosis Emerging Drugs
*
MN-166: MediciNova
*
RNS60: Revalesio
*
VM202: Helixmith
*
QRL-201: QurAlis Corporation
Amyotrophic Lateral Sclerosis Companies
Over 75 leading companies are actively developing therapies for Amyotrophic Lateral Sclerosis (ALS), with MediciNova having the most advanced candidates currently in Phase II/III clinical trials.
DelveInsight's report covers around 80+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Amyotrophic Lateral Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Amyotrophic Lateral Sclerosis Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Amyotrophic Lateral Sclerosis Therapies and Key Companies: Amyotrophic Lateral Sclerosis Clinical Trials and advancements [https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Amyotrophic Lateral Sclerosis Pipeline Therapeutic Assessment
- Amyotrophic Lateral Sclerosis Assessment by Product Type
- Amyotrophic Lateral Sclerosis By Stage
- Amyotrophic Lateral Sclerosis Assessment by Route of Administration
- Amyotrophic Lateral Sclerosis Assessment by Molecule Type
Download Amyotrophic Lateral Sclerosis Sample report to know in detail about the Amyotrophic Lateral Sclerosis treatment market @ Amyotrophic Lateral Sclerosis Therapeutic Assessment [https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Amyotrophic Lateral Sclerosis Current Treatment Patterns
4. Amyotrophic Lateral Sclerosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Amyotrophic Lateral Sclerosis Late-Stage Products (Phase-III)
7. Amyotrophic Lateral Sclerosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Amyotrophic Lateral Sclerosis Discontinued Products
13. Amyotrophic Lateral Sclerosis Product Profiles
14. Amyotrophic Lateral Sclerosis Key Companies
15. Amyotrophic Lateral Sclerosis Key Products
16. Dormant and Discontinued Products
17. Amyotrophic Lateral Sclerosis Unmet Needs
18. Amyotrophic Lateral Sclerosis Future Perspectives
19. Amyotrophic Lateral Sclerosis Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Amyotrophic Lateral Sclerosis Pipeline Reports Offerings [https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=amyotrophic-lateral-sclerosis-clinical-trials-companies-therapies-pipeline-ionis-pharmaceuticals-1st-biotherapeutics-scholar-rock-revalesio-quralis-corporation-sanofi-medicinova-helixmith]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Amyotrophic Lateral Sclerosis Clinical Trials, Companies, Therapies, Pipeline | Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith here
News-ID: 4155061 • Views: …
More Releases from ABNewswire
PCSK9 Inhibitors Market Landscape: Clinical Pipeline, Competitive Strategies, an …
DelveInsight's PCSK9 Inhibitors Market Report highlights strong growth potential, with the 7MM market projected to expand significantly by 2034 from USD 2B in 2023. The U.S. leads with ~USD 900M. Key players include Sanofi, Regeneron, Amgen, AstraZeneca, LIB Therapeutics, Merck, Novartis, Alnylam, Aqur Biosciences, and CiVi Biopharma. Current leaders PRALUENT and REPATHA dominate, while pipeline assets like LIB003 and MK-0616 signal the next wave of innovation.
DelveInsight's comprehensive [https://www.delveinsight.com/report-store/pcsk9-inhibitors-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report, provides…
Bronchiectasis Treatment Landscape: FDA Approves BRINSUPRI, First Disease-Modify …
DelveInsight Business Research's latest report highlights the transformative impact of the FDA's approval of BRINSUPRI (brensocatib) by Insmed Incorporated (NASDAQ: INSM). This landmark approval marks the first disease-specific therapy for bronchiectasis, offering new hope for over one million patients suffering from this chronic, progressive lung disease characterized by irreversible bronchial airway dilation and impaired mucociliary function.
Key Bronchiectasis Market Highlights
*
BRINSUPRI's approval is expected to be a key bronchiectasis market driver,…
Recurrent Respiratory Papillomatosis Treatment Landscape: FDA Approves PAPZIMEOS …
DelveInsight Business Research's latest report highlights the transformative impact of the FDA's approval of PAPZIMEOS (zopapogene imadenovec-drba) by Precigen, Inc. (NASDAQ: PGEN). This landmark approval marks the first FDA-approved therapy for recurrent respiratory papillomatosis in history, offering unprecedented hope for thousands of patients suffering from this rare and debilitating condition caused by human papillomavirus infection.
Key Recurrent Respiratory Papillomatosis Market Highlights
*
PAPZIMEOS approval represents a paradigm shift in the recurrent respiratory…
Fibromyalgia Treatment Landscape: FDA Approves TONMYA, First New Therapy in 15 Y …
DelveInsight Business Research's latest report highlights the transformative impact of the FDA's approval of TONMYA (cyclobenzaprine HCl sublingual tablets) by Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP). This landmark approval marks the first new fibromyalgia treatment approved by the FDA in more than 15 years, offering new hope for millions of patients suffering from this debilitating chronic pain condition.
Key Fibromyalgia Market Highlights
*
TONMYA's approval is expected to be a key driver…
More Releases for Late
Late Night Revelry Awaits at The Winslow Lounge - NYC's Premier Late-Night Desti …
Image: https://www.getnews.info/wp-content/uploads/2024/06/1713864312.jpeg
New York, NY - The Winslow Lounge, located in the heart of the East Village, has quickly become the premier late-night destination [https://thewinslownyc.com/late-night-bar-nyc/] in New York City. With its vibrant atmosphere, exciting entertainment options, delicious food and drinks, and lively events, The Winslow offers an unforgettable nightlife experience.
"We wanted to create a place in NYC where people could truly let loose and have an amazing time," said Mark Tafoya,…
Desperate Puppy Seeks Rescue Before It’s Too Late!
FOR IMMEDIATE RELEASE
Tucson AZ, December 14th, 2021
The StarBarksCoffee.com rescue team was recently assaulted and threatened with being shot for assisting an abused, entangled puppy.
This Video of a neglected puppy desperately seeking rescue from a mentally unstable and violently aggressive owner was taken recently at an RV park in Texas during our annual "Journey Across America" in support of Animal Welfare.
We've contacted Texas authorities, but the Sheriff’s Department informed us the…
Transform your Traditional Businesses Before Its Too Late
Mob Inspire, an app development company has disrupted many industries by providing innovative software solutions to traditional businesses. We understand the rapidly changing tech environment and therefore equipt ourselves with those skills and tech tools which enable us to deal with challenging situations efficiently.
Mob Inspire takes the leverage of the latest tech trends like Blockchain, IoT and Cloud to deliver high-end products to its clients. The popularity…
Late-Night Treats for Late-Night Peeps
WHAT: La Motta’s, the neighborhood favorite in Boston’s SoWa District, is rolling out the late-night red carpet for its hospitality industry folks and friends, with Chef de Cuisine Justin Winter’s creative twists on after-hours snacks. Available every Sunday - Thursday from 10:00PM to last call, La Motta’s is the neighborhood joint for a late-night bash with flavorful bites and brews.
Launching Sunday, February 26th, 2017, guests can expect flavorful options…
Late payment – the hidden challenge facing Europe's businesses
A recent Europe-wide business survey has revealed no improvement in the pressure on European businesses from customers’ late payments, with 55 per cent of businesses across Europe reporting late payments resulting in loss of income, 63 per cent claiming additional pressures on liquidity, and 50 per cent citing late payments as having a direct impact on company growth.
In the Republic of Ireland, 47 per cent of businesses surveyed claimed…
Construction in Bulgaria to stabilise in late 2011
In the coming years Bulgaria's construction sector will start to grow slowly following the hard years of the economic slowdown, although no spectacular changes are expected in the short run. After substantial restructuring of the sector moderate construction market recovery in the period 2012-2013 is expected. Until 2015 the sector will grow on the back of the large-scale infrastructure projects related to EU funds.
According to the report “Construction sector in…
